2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Bioinformatics, Clinical Procedures, Emerging Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Study Population, Human, Adult
PAPER

5729 Cure fraction and long-term survival in systemic AL amyloidosis: A population-adjusted analysis of 2,384 patients

Vaishali Sanchorawala, MD, Ali Greatsinger2, Frederick L Ruberg, MD3, John Mark L Sloan Jr, MD4, Omar K Siddiqi, MD5, Deepa M Gopal, MD6, Shabatun M Islam, MD7, Deandre M King, MD8, Ashish M Verma, MD9, Umut Selamet, MD10, Ava Bakhtyari, MD11, Natasha J Burke12, James Signorovitch, PhD13, Andrew Staron, MD14
1 Analysis Group, Inc, Boston, Massachusetts, United States, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
2 Analysis Group, Inc, Boston, Massachusetts, United States
3 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
4 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
5 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
6 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
7 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
8 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
9 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
10 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
11 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
12 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
13 Analysis Group, Inc, Boston, Massachusetts, United States
14 Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States

Background: Deepening treatment responses and prolonged survival have made cure a realistic consideration in AL amyloidosis. Cure fraction represents the proportion of patients whose survival approximates that of the general population and provides a framework for evaluating the possibility of cure. In multiple myeloma, population-adjusted cure fraction estimates have approached 15‒30% in the modern era. Whether similar gains have been achieved in AL amyloidosis, where long-term outcomes depend not only on hematologic response but also on recovery from organ damage, remains undefined. This study estimated the cure fraction in AL amyloidosis and characterized patients achieving very long-term survival (≥20 years).

Methods: We analyzed consecutive consented patients with AL amyloidosis evaluated at our center from January 1990 through March 2026. Cure fraction was estimated using a population-adjusted non-mixture cure model incorporating age- and sex-matched background mortality based on attained age. Survival was indexed from initial evaluation and censored at last follow-up. Long-term survivors were defined as patients alive ≥20 years after initial evaluation.

Results: Among 2,384 patients (mean age 61 ± 11 years; 60% male) with a median follow-up of 2.3 years (IQR 0.6‒6.5), median overall survival was 2.9 years (95% CI: 2.6‒3.2), with estimated 10- and 15-year survival rates of 23% and 12%, respectively. The overall population-adjusted cure fraction was 16%, indicating that approximately one in six patients achieved survival comparable to age- and sex-matched peers. This fraction increased substantially over time, from 5% among patients evaluated before 2000 to 27% among those evaluated between 2010 and 2019. Among patients evaluated after 2020, the estimated cure fraction was 74%; however, this estimate is limited by short follow-up and high censoring.

Even among patients achieving a hematologic complete response (CR), the population-adjusted cure fraction was only 29%, compared with 7% among those not achieving CR. Although CR conferred an approximately fourfold higher likelihood of cure, the finding that over 70% of patients in CR did not attain the expected survival of the general population underscores that hematologic response alone is insufficient and that persisting organ dysfunction from amyloid deposition remains a critical determinant of long-term outcomes.

Durable treatment-free remission was observed in a subset: among 1,634 patients with available treatment data, 107 (5%) remained treatment-free for ≥10 years after last therapy. Twenty-six patients survived ≥20 years after initial evaluation. Compared with the overall cohort, these long-term survivors were younger at diagnosis (mean age 52 vs 61 years), more frequently achieved durable hematologic CR (50% vs 20%), and were more often treated with high-dose melphalan and stem cell transplantation (HDM/SCT) (81% vs 33%). Organ transplantation was also more frequent among long-term survivors, including kidney (19% vs 3%) and heart transplantation (8% vs 2%). Despite survival approaching that of the general population, late morbidity related to organ involvement and prior therapy remained evident.

Conclusions: Approximately one in six patients with AL amyloidosis achieved survival comparable to age- and sex-matched peers, with the cure fraction rising from 5% before 2000 to 27% in the 2010‒2019 era. However, organ damage imposes a ceiling on cure even when deep hematologic responses are achieved: only 29% of patients in CR attained population-adjusted cure, highlighting the need for therapeutic strategies that encompass organ preservation and recovery. Long-term survivors were characterized by younger age, deep hematologic response, receipt of HDM/SCT, and greater utilization of organ transplantation, though excess morbidity may persist even among those apparently cured.

Vaishali Sanchorawala, MD: Janssen - Honoraria; Gate Bioscience - Honoraria; Eidos Therapeutics - Honoraria; GlaxoSmithKline - Honoraria; Prothena - Honoraria; AbbVie - Honoraria; Alexion Pharmaceuticals - Honoraria; Janssen - Research Funding; Caelum Biosciences - Research Funding; Takeda - Research Funding; Immix BioPharma - Research Funding; Karyopharm Theraputics - Research Funding; Celgene - Research Funding; Prothena - Research Funding; Gate Bioscience - Research Funding; Oncopeptide - Research Funding; AbbVie - Consultancy (Includes expert testimony); Caelum Biosciences - Consultancy (Includes expert testimony); Gate Bioscience - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Proclara - Consultancy (Includes expert testimony); Protego Biopharma - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony)